Skip to main content
Grafa
Health
Memphasys secures Turkish registration and initial sales
Image for illustrative purposes only. Not a real photo.

Memphasys secures Turkish registration and initial sales

Share
  • Memphasys received product registration for its Felix System in Turkey and completed its first commercial sale.
  • Following the update, the Memphasys share price was unchanged at $0.005.
  • The company aims to expand commercial distribution into 165 assisted reproduction technology centres across Turkey.

Memphasys (ASX:MEM) secured product registration in Turkey for its Felix System, enabling the immediate commencement of commercial sales.

The market approval follows the expansion of the company's distribution agreement in September 2025 and the completion of local team training.

A/Prof Hassan Bakos, Memphasys Director of Clinical Partnerships and Growth, commented, "The initial sale and distributor training give us a practical starting point in a large, established IVF market."

The initial commercial order in the country comprises 100 Felix cartridges and two consoles under the International Technical Legacy agreement.

Memphasys noted that Turkey operates an established assisted-reproduction sector undertaking approximately 75,000 technology treatment cycles annually.

Following the announcement, the Memphasys share price was unchanged at $0.005.

The registration is officially recorded on Turkey's national Product Tracking System.

This market entry follows similar recent international expansion steps, including regulatory clearance in Vietnam and commercial progress in Poland.

Frequently asked questions